NRXP receives Nasdaq delisting warning for bid price below $1; appoints Stephen Willard as CEO

NRX Pharmaceuticals, Inc.

Nasdaq notified NRXP on July 12, 2022 of non-compliance with minimum bid price rule (below $1 for 30 days); 180-day cure period to Jan 9, 2023.
Stephen Willard appointed CEO and director effective July 12, 2022; base salary $500k/yr, target bonus $250k, 1M restricted shares vesting over 3 years.
Interim CEO Robert Besthof returns to roles as Head of Operations and Chief Commercial Officer.
Mr. Willard previously CEO of Cellphire Therapeutics and Flamel Technologies; also a National Science Board presidential appointee (2018-2024).

item 3.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Robert Besthof

Head of Operations and Chief Commercial Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2022-07-12
Successor: Stephen Willard
Filed: July 15, 2022, 7:59 PM ET

With the appointment of Mr. Willard as the new CEO, the interim CEO, Mr. Robert Besthof, has agreed to remain with the Company and will resume his responsibilities as Head of Operations Officer and Chief Commercial Officer for the Company.

Appointed

Stephen Willard

Chief Executive Officer and Director

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2022-07-12
Successor: Robert Besthof
Filed: July 15, 2022, 7:59 PM ET

On July 12, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “Company”) appointed Stephen Willard, 61, to serve as Chief Executive Officer (“CEO”) of the Company and a member of the Board of Directors, with immediate effect.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Besthof changed role as Head of Operations and Chief Commercial Officer at NRX Pharmaceuticals, Inc..

Action: resume responsibilities
Role: Head of Operations and Chief Commercial Officer

Exact text from the filing

With the appointment of Mr. Willard as the new CEO, the interim CEO, Mr. Robert Besthof, has agreed to remain with the Company and will resume his responsibilities as Head of Operations Officer and Chief Commercial Officer for the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Willard was appointed as Chief Executive Officer and Director at NRX Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer and Director

Exact text from the filing

On July 12, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “Company”) appointed Stephen Willard, 61, to serve as Chief Executive Officer (“CEO”) of the Company and a member of the Board of Directors, with immediate effect.

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950142-22-002222

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.